Skip to main content
. Author manuscript; available in PMC: 2014 May 28.
Published in final edited form as: J Am Coll Cardiol. 2013 Mar 26;61(21):2169–2179. doi: 10.1016/j.jacc.2013.02.047

Table 4.

Relative risks and 95% confidence intervals for peripheral artery disease according to level of AA to MDA-LDL.

IgG AA IgM AA
WOMEN

Per 1 SD
increase
Tertile Per 1 SD
increase
Tertile
log(IgG AA) 1 2 3 1 2 3
Range (RLU) 1,465-6,580 6,581-11,017 11,018-57,009 Range (RLU) 2,013-15,741 15,742-22,494 22,495-77,968
No. Cases 144 40 56 48 No. Cases 144 50 34 60
Model 1 1.16 (0.96-1.40) 1.0 (ref) 1.53 (0.95-2.45) 1.26 (0.78-2.02) Model 1 1.13 (0.95-1.36) 1.0 (ref) 0.59 (0.35-0.98) 1.34 (0.84-2.13)
Model 2 1.16 (0.95-1.42) 1.0 (ref) 1.48 (0.89-2.46) 1.32 (0.80-2.17) Model 2 1.10 (0.91-1.34) 1.0 (ref) 0.57 (0.34-0.97) 1.32 (0.81-2.17)
Model 3 1.10 (0.88-1.37) 1.0 (ref) 1.42 (0.79-2.53) 1.13 (0.65-1.96) Model 3 1.00 (0.80-1.26) 1.0 (ref) 0.47 (0.26-0.85) 1.05 (0.60-1.85)

MEN

Per 1 SD
increase
Tertile Per 1 SD
increase
Tertile
log(IgG AA) 1 2 3 1 2 3
Range (RLU) 485-1,940 1,941-3,690 3,691-64,956 Range (RLU) 732-7,203 7,204-11,833 11,834-94,623
No. Cases 143 57 40 46 No. Cases 143 45 44 54
Model 1 0.94 (0.79-1.12) 1.0 (ref) 0.57 (0.35-0.93) 0.73 (0.46-1.15) Model 1 1.13 (0.96-1.34) 1.0 (ref) 0.91 (0.56-1.49) 1.25 (0.80-1.97)
Model 2 0.87 (0.71-1.06) 1.0 (ref) 0.52 (0.30-0.89) 0.54 (0.32-0.92) Model 2 1.18 (0.97-1.43) 1.0 (ref) 0.83 (0.48-1.43) 1.17 (0.70-1.96)
Model 3 0.84 (0.67-1.06) 1.0 (ref) 0.58 (0.31-1.08) 0.52 (0.29-0.95) Model 3 1.13 (0.93-1.39) 1.0 (ref) 1.02 (0.55-1.87) 1.26 (0.71-2.23)

Model 1: adjusted for matching factors (age, race (women only), month of blood draw, fasting status, and smoking status).

Model 2: adjusted for matching factors, triglycerides, HDL-C, LDL-C, hsCRP, and HbA1c.

Model 3: adjusted for matching factors, triglycerides, HDL-C, LDL-C, hsCRP, HbA1c, parental history of MI before age 60, pack-years of smoking, physical activity, hypertension, diabetes, hypercholesterolemia, BMI, aspirin use and postmenopausal hormone use (women only).